LYTAK1

**LYTAK1** is a novel, specific small molecule inhibitor of transforming growth factor-β-activated kinase 1 (TAK1). TAK1 is a key mediator in several cell signaling pathways, including those involved in cancer progression, inflammatory responses, and epithelial-mesenchymal transition (EMT). LYTAK1 blocks TAK1 phosphorylation and activity, inhibits downstream activation of nuclear factor kappa B (NF-κB), Smad2, ERK, and AKT pathways, and reduces proliferation, migration, and EMT in KRAS mutant colorectal cancer (CRC) cells, ovarian cancer cells, and retinal pigment epithelium (RPE) cells. LYTAK1 is orally bioavailable and has shown efficacy in preclinical models, suppressing tumor xenograft growth and attenuating pro-inflammatory cytokine production and endotoxin shock in animal studies. Its primary indications investigated are cancers with TAK1 overactivation (such as CRC and ovarian cancer) and proliferative vitreoretinopathy (PVR)[1][3][5][6].

Brand names

LYTAK1LYTAK-1LYTAK 1

Other names

LYTAK1LYTAK-1LYTAK 1